Analyst Notes: Neurologists proving a tough bunch to impress with current multiple sclerosis treatment options

FirstView surveyed 100 neurologists in the US, and 150 in the EU5 countries, to gauge brand loyalty and satisfaction with current multiple sclerosis treatments. The results, now available in FirstView's NPS+ Multiple Sclerosis, show some interesting dynamics and regional differences.

In both regions surveyed brands include Aubagio, Avonex, Betaseron/Betaferon, Copaxone, Gilenya, Lemtrada, Plegridy, Rebif, Tecfidera, Tysabri and Zinbryta. In the US, Ocrevus was also included.

In the US and Europe, only two brands managed to eke out a positive NPS, with scores slightly higher in the US compared to Europe. These brands are all well-established treatments, suggesting that physicians need long-term experience before they feel comfortable recommending treatments to colleagues.

Brand loyalty and satisfaction scores are also low in both regions, with only 12 percent to 14 percent of doctors claiming to be satisfied with treatment options and loyal to one brand. All other physicians are unhappy with the treatments they have access to, and share their loyalty across multiple brands.

A common theme across all of FirstView's NPS+ research is that Passives (i.e. those respondents that give brands a NPS of between 7 and 8) could hold the key to significant market share gains. This is particularly true in the US, where three of the 12 brands included in the survey achieve Passive scores in the region of 40 percent. The message is clear; it's time to appease the passives. Big market share gains could come if some companies focused on this group of physicians. Is your brand one of them?

Finally, for some drugs, specific brand messages are resonating more with doctors, even amongst Passives and Detractors. Clinical attributes lead, with safety and efficacy dominating importance tables, but other drug attributes must not be ignored.

Full survey results now available

The latest FirstWord report, NPS+ Multiple Sclerosis is now available in two versions – one based on survey results from the US and the other on the EU5 countries (France, Germany, Italy, Spain and the UK). For more information, contact FirstWord or call +1 212-220-0880 or +44(0)20.7665.9240

To read more Analyst Notes articles, click here.